Hyperuricemia - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hyperuricemia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Hyperuricemia - Pipeline Review, H1 2016', provides an overview of the Hyperuricemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hyperuricemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperuricemia
- The report reviews pipeline therapeutics for Hyperuricemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hyperuricemia therapeutics and enlists all their major and minor projects
- The report assesses Hyperuricemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hyperuricemia

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hyperuricemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hyperuricemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Hyperuricemia Overview 8
Therapeutics Development 9
Pipeline Products for Hyperuricemia - Overview 9
Pipeline Products for Hyperuricemia - Comparative Analysis 10
Hyperuricemia - Therapeutics under Development by Companies 11
Hyperuricemia - Therapeutics under Investigation by Universities/Institutes 12
Hyperuricemia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Hyperuricemia - Products under Development by Companies 16
Hyperuricemia - Products under Investigation by Universities/Institutes 17
Hyperuricemia - Companies Involved in Therapeutics Development 18
AstraZeneca Plc 18
CymaBay Therapeutics, Inc. 19
Jiangsu Hengrui Medicine Co., Ltd. 20
Kissei Pharmaceutical Co., Ltd. 21
Nippon Chemiphar Co., Ltd. 22
Polaris Pharmaceuticals, Inc. 23
Takeda Pharmaceutical Company Limited 24
Teijin Pharma Limited 25
Hyperuricemia - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(allopurinol + lesinurad) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
arhalofenate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
febuxostat - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
febuxostat XR - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
JPH-367 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
KGO-2142 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
KGO-2173 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
NC-2500 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pegadricase - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
RDEA-3170 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Inhibit Human Uric Acid Transporter 1 for Hyperuricemia - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
TMX-049 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
XEN-102 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Hyperuricemia - Recent Pipeline Updates 54
Hyperuricemia - Dormant Projects 58
Hyperuricemia - Discontinued Products 59
Hyperuricemia - Product Development Milestones 60
Featured News & Press Releases 60
Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11 60
Jun 30, 2015: New Indication for Teijin Pharma's Febuxostat in Europe 61
Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat 61
Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric 62
Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat 63
Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat 63
Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea 64
May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan 64
Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67 65
Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68

List of Tables

Number of Products under Development for Hyperuricemia, H1 2016 9
Number of Products under Development for Hyperuricemia - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Hyperuricemia - Pipeline by AstraZeneca Plc, H1 2016 18
Hyperuricemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016 19
Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 20
Hyperuricemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 21
Hyperuricemia - Pipeline by Nippon Chemiphar Co., Ltd., H1 2016 22
Hyperuricemia - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 23
Hyperuricemia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 24
Hyperuricemia - Pipeline by Teijin Pharma Limited, H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Assessment by Combination Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Mechanism of Action, H1 2016 31
Number of Products by Stage and Route of Administration, H1 2016 33
Number of Products by Stage and Molecule Type, H1 2016 35
Hyperuricemia Therapeutics - Recent Pipeline Updates, H1 2016 54
Hyperuricemia - Dormant Projects, H1 2016 58
Hyperuricemia - Discontinued Products, H1 2016 59